Perente I, et al. - A sum of 116 eyes were studied to research over the vascularization end limit of the peripheral retina and also to define the vascular development models of subjects with aggressive posterior retinopathy of prematurity (APROP), treated with a single intravitreal injection of bevacizumab. Researchers obtained the information from fluorescein angiography (FA) for proper treatment decision at a late period of APROP subjects treated with bevacizumab. They reported an increase in the risk for late complications with fluorescein leakage and persistent avascular areas detected at FA at 90–100 gestational weeks. They noted FA capable of detecting the abnormalities which could not be identified through an indirect ophthalmoscope. Hence, it was considered valuable for follow-up and further treatments of APROP.